Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS

  1. Home
  2. news
  3. Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS

Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS

Encouraging data about first treatment of two SOD1 ALS patients with Apic's gene therapy published in New England Journal of Medicine
Previous
FDA starts priority review of Orphazyme's therapy in Niemann Pick Disease
Next

Recent Posts

  • Prilenia enrolls first ALS patient in their Phase II / III study
  • Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
  • Prilenia shows positive effect on functional capacity in Huntigton’s Disease
  • Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
  • Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board